UCART 19

Drug Profile

UCART 19

Alternative Names: CD19CAR/RQR8+_TCRαβ–_T-cells; UCART19

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellectis
  • Developer Cellectis; Pfizer; Servier
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia

Most Recent Events

  • 27 Jul 2017 Cellectis and MolMed agree to develop and produce allogeneic CAR-T products for Cancer
  • 29 Jun 2017 Servier in-licenses viral vectorization technology from Transgene
  • 09 Mar 2017 US FDA approves IND application for UCART 19 in Acute lymphoblastic leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top